HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

<ul>
<li>The expansion of the scope of positioning directly reflects the change in the importance of pharmaceutical industry in the minds of the top level, which is very pivotal.</li>
<li>The determination to abandon old development mode, and promote real innovation and high-quality internationalization remains unchanged. So, companies need to develop at a higher level and a larger stage.</li>
<li>Once achieved, it means that China's pharmaceutical industry will have another radical change after 2015, leading the industry to another new phase of growth.</li>
</ul>


The expansion of the scope of positioning directly reflects the change in the importance of pharmaceutical industry in the minds of the top level, which is very pivotal.
The determination to abandon old development mode, and promote real innovation and high-quality internationalization remains unchanged. So, companies need to develop at a higher level and a larger stage.
Once achieved, it means that China's pharmaceutical industry will have another radical change after 2015, leading the industry to another new phase of growth.


Interpretation of The "14th Five-Year Plan" For the Development of China Pharmaceutical Industry

<ul>
<li>The "14th Five-year Plan" for the development of pharmaceutical industry was released. China's attention to the internationalization development of the pharmaceutical industry has risen to a new height.</li>
<li>There are still many real clinical needs that need to be addressed through innovation. So, this requires a change in thinking and a broadening of cognitive boundaries.</li>
<li>For some biotech, it is very difficult to have successful commercialization without differentiating products. Companies have to know how to “define” a good product,which is the right way to innovate.</li>
</ul>


The "14th Five-year Plan" for the development of pharmaceutical industry was released. China's attention to the internationalization development of the pharmaceutical industry has risen to a new height.
There are still many real clinical needs that need to be addressed through innovation. So, this requires a change in thinking and a broadening of cognitive boundaries.
For some biotech, it is very difficult to have successful commercialization without differentiating products. Companies have to know how to “define” a good product,which is the right way to innovate.


China Healthcare Weekly (Feb.4)- "14th Five-Year Plan" Of Pharmaceuticals, the Right Way to Innovate

<ul>
<li>Last week, the 7th national volume-based purchase (VBP) began, involving 208 product specifications and 59 varieties.</li>
<li>We summaries the competitive landscape and outlook of both domestic and foreign pharmaceutical companies in this VBP.</li>
<li>Most investors may not have experienced July 22, 2015, so there is no reason to dismiss the prospects of China's healthcare industry because of the correction in the short term. </li>
</ul>


Last week, the 7th national volume-based purchase (VBP) began, involving 208 product specifications and 59 varieties.
We summaries the competitive landscape and outlook of both domestic and foreign pharmaceutical companies in this VBP.
Most investors may not have experienced July 22, 2015, so there is no reason to dismiss the prospects of China's healthcare industry because of the correction in the short term. 


China Healthcare Weekly (Jan.28) - 7th National VBP, Taking History as a Mirror, Confidence Rebuilt

<ul>
<li>Last week, we saw some rebounds in the healthcare sector, and many investors begin to believe that a complete reversal is imminent. </li>
<li>Our view is that this is <strong>a temporary rebound</strong> after continuous pull-back due to the broken logic, rather than <strong>a complete reversal</strong>.We recommend investors to see the rebound rationally.</li>
<li>In terms of the future direction of stock price, we analyze it based on three scenarios.</li>
</ul>


Last week, we saw some rebounds in the healthcare sector, and many investors begin to believe that a complete reversal is imminent. 
Our view is that this is a temporary rebound after continuous pull-back due to the broken logic, rather than a complete reversal.We recommend investors to see the rebound rationally.
In terms of the future direction of stock price, we analyze it based on three scenarios.


The Insecure Rebound in Healthcare Sector and the Future Direction of Stock Price (2022)

Equity Capital Markets

Betta Pharmaceuticals   / Equity Capital Markets

<ul>
<li>If the R&amp;D pipeline projects are not recognized by international capital,the main reason could be either the product development progress is lagging behind or the projects are not good enough.</li>
<li>The real innovative drugs would not be affected by generics that easily, and are to overturn the size of the old drug market.</li>
<li>The real risk of Betta would be revealed in the next few years as VBP promotes. So, we are conservative about the Company’s outlook at the current stage.</li>
</ul>


If the R&amp;D pipeline projects are not recognized by international capital,the main reason could be either the product development progress is lagging behind or the projects are not good enough.
The real innovative drugs would not be affected by generics that easily, and are to overturn the size of the old drug market.
The real risk of Betta would be revealed in the next few years as VBP promotes. So, we are conservative about the Company’s outlook at the current stage.


Pre-IPO Betta Pharmaceuticals - Lack of Staying Power

China

Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Innovent Biologics Inc (1801 HK)

Interpretation of The "14th Five-Year Plan" For the Development of China Pharmaceutical Industry

For the newly released "14th Five-year Plan" of China pharmaceutical industry, we analyzed key points and our interpretation. Once achieved, it...

Xinyao (Criss) Wang

China Healthcare Weekly (Feb.4)- "14th Five-Year Plan" Of Pharmaceuticals, the Right Way to Innovate

We analyzed important points of the "14th Five-year Plan" for pharmaceutical industry. Meanwhile, the right way to innovate requires a broadening...

Xinyao (Criss) Wang

China Healthcare Weekly (Jan.28) - 7th National VBP, Taking History as a Mirror, Confidence Rebuilt

We analyzed the competitive landscape of 7th national VBP. Taking history as a mirror, the 2015 healthcare reform could be a good reference.So,...

Xinyao (Criss) Wang

The Insecure Rebound in Healthcare Sector and the Future Direction of Stock Price (2022)

The rebound in China healthcare sector last week was a temporary rebound rather than a complete reversal. In terms of future direction of stock...

Xinyao (Criss) Wang

Pre-IPO Betta Pharmaceuticals - Lack of Staying Power

The insight analyzed Betta about key products such as Icotinib, Ensartinib, MIL60, CM082, concerns on slow product iteration,fierce...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)